Jaguar Health

Jaguar Health is a commercial stage pharmaceuticals company headquartered in San Francisco, California. The company employs 15 people and generates revenue exceeding $10,000. Jaguar Health is a publicly traded company listed on the NASDAQ stock exchange under the ticker symbol JAGX. Jaguar Health specializes in developing plant-based, non-opioid prescription medicines for both humans and animals suffering from gastrointestinal distress, particularly chronic diarrhea. The company's portfolio includes products for various GI conditions. Jaguar operates through several subsidiaries, including Napo Pharmaceuticals, which focuses on developing human pharmaceuticals from sustainably harvested rainforest plants. In addition, Jaguar holds a majority stake in Napo Therapeutics S.p.A., an Italian corporation dedicated to expanding access to crofelemer, a key product in Europe. Jaguar also has a subsidiary focused on animal health, operating under the tradename Jaguar Animal Health. Furthermore, through a joint venture with Filament Health called Magdalena Biosciences, Jaguar is researching and developing plant-derived medicines for mental health conditions like ADHD. For more information on Jaguar Health and its subsidiaries, please visit their respective websites: www.jaguar.health, www.napopharma.com, napotherapeutics.com, and magdalenabiosciences.com.